Topamax® (topiramate): Updated warnings and precautions on visual field defects

Janssen, a division of Johnson & Johnson Pte Ltd, would like to alert healthcare professionals to the potential risk of visual field defects associated with Topamax®. In double-blind, controlled monotherapy epilepsy trials, visual field defects were reported at a frequency of 0% to 1.3% in Topamax®-treated adult patients. Based on cumulative data from a recent review of post-marketing safety databases and clinical trials, the package insert for Topamax® will be updated to reflect new safety information and guidance on visual field defects. Healthcare professionals are advised to consider discontinuing Topamax® if visual problems occur at any time during treatment with this drug. Please refer to the letter for more information

 
 
Healthcare professional, Therapeutic Products
Published:

Dear Healthcare Professional Letters

12 Dec 2019

Only abstracts of the Dear Healthcare Professional Letters (DHCPL) are provided on this website. Details of the letters can be found on the MOH Alert System, which is accessible via the Health Professionals Portal (HPP). HPP is a one-stop portal for all healthcare professionals in Singapore. Dentists, medical doctors and pharmacists may access HPP at https://www.moh.gov.sg/hpp/, and follow the procedures below to access the MOH Alert system.

Step 1: On the top navigation ribbon of webpage, select 'For Healthcare Professionals' followed by 'Health Professionals Portal' and click on the choice of profession. User will be redirected to the specific HPP webpage for the selected profession.

Step 2: Click on the Restricted Content icon on the left panel of webpage and login via SingPass.

Step 3: Click on the MOH Alert icon under ‘Applications’ section

Step 4: Click on the Drug Alert tab to view the DHCPLs.